Quince Therapeutics Stock Forecast
NASDAQ: QNCXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 30.69 +4.52%
QNCX analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$75.43+156.91%
- Strong buy 1
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Quince Therapeutics (2026-10-09), 7 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $75.43, with a high estimate of $98.00 and a low estimate of $65.00. The average target implies upside of 156.9% from the current price of $29.36.
The spread between the highest and lowest targets is 50.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for QNCX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 13% |
| Buy | 6 | 75% |
| Hold | 1 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $65.00 | +121.39% |
| Average target | $75.43 | +156.91% |
| High target | $98.00 | +233.79% |